TherapeuticsMD (DB:29TA) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

29TA Aperçu des actions

Operates as a pharmaceutical royalty company in the United States.

29TA analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	1/6
Performances passées	0/6
Santé financière	2/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 18.48% par an

Analyse des risques

Les actions sont très illiquides

Capitaux propres négatifs

N'a pas de capitalisation boursière significative ( €58M )

Les actionnaires ont été dilués au cours de l'année écoulée

+ 1 plus de risques

TherapeuticsMD, Inc. Concurrents

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€66.1m

Apontis Pharma

XTRA:APPH

€53.3m

MPH Health Care

DB:93M1

€102.8m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour TherapeuticsMD
Historique des cours de bourse
Prix actuel de l'action	US$9.75
Plus haut sur 52 semaines	US$34.75
Plus bas sur 52 semaines	US$0.11
Bêta	1.43
1Variation sur 1 mois	0%
Variation sur 3 mois	1.56%
Variation sur 1 an	-67.50%
3Variation sur 3 ans	-94.13%
Variation sur 5 ans	-95.37%
Évolution depuis l'introduction en bourse	-95.21%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	29TA	DE Pharmaceuticals	DE Marché
7D	0%	3.1%	4.5%
1Y	-67.5%	-12.1%	13.4%

Rendement vs Industrie: 29TA a sous-performé le secteur German Pharmaceuticals qui a rapporté -13.5 % au cours de l'année écoulée.

Rendement vs marché: 29TA a sous-performé le marché German qui a rapporté 4.7 % au cours de l'année écoulée.

Volatilité des prix

Is 29TA's price volatile compared to industry and market?
29TA volatility
29TA Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: 29TA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de 29TA au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2008	416	Brian Bernick	www.therapeuticsmd.com

TherapeuticsMD, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de TherapeuticsMD se comparent-ils à sa capitalisation boursière ?
29TA statistiques fondamentales
Capitalisation boursière	€58.33m
Bénéfices(TTM)	-€27.21m
Recettes(TTM)	€92.29m

0.6x

Ratio P/S

-2.1x

Ratio P/E

Le site 29TA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
29TA compte de résultat (TTM)
Recettes	US$91.98m
Coût des recettes	US$19.62m
Marge brute	US$72.36m
Autres dépenses	US$99.48m
Les revenus	-US$27.12m

Derniers bénéfices déclarés

Jun 30, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-2.86
Marge brute	78.67%
Marge bénéficiaire nette	-29.49%
Ratio dettes/capitaux propres	-348.3%

Quelles ont été les performances à long terme de 29TA?

Voir les performances historiques et les comparaisons

29TA Aperçu des actions

Récompenses

Analyse des risques

TherapeuticsMD, Inc. Concurrents

DB:0RX

€65.0m

XTRA:HIGH

€66.1m

XTRA:APPH

€53.3m

DB:93M1

€102.8m

Historique des prix et performances

Nouvelles et mises à jour récentes

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Recent updates

TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024

TherapeuticsMD, Inc. Announces Executive Changes

TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023

TherapeuticsMd, Inc. Announces Executive Changes

Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc.

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board

TherapeuticsMD, Inc. Appoints Justin Roberts as A Director

TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index

TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners

Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million.

Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera®

First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021)

TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022

Forecast breakeven date pushed back to 2024

GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million.

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair

Independent Director recently bought €510k worth of stock

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)

Forecast to breakeven in 2023

Executive Vice President of Operations Edward Borkowski has left the company

TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector

Independent Director recently bought €619k worth of stock

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index

TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)

Revenue beats expectations

TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high: €1.31

TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health

New 90-day low: €0.94

New 90-day low: €1.03

Revenue beats expectations

Third quarter 2020 earnings released: US$0.12 loss per share

TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

New 90-day low: €1.06

TherapeuticsMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA

First half earnings released

TherapeuticsMD, Inc. to Report Q2, 2020 Results on Aug 06, 2020

New 90-day high - €1.92

TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from S&P Pharmaceuticals Select Industry Index

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

TherapeuticsMD, Inc. Résumé des fondamentaux

0.6x

-2.1x

Bénéfices et recettes